<DOC>
	<DOCNO>NCT00117689</DOCNO>
	<brief_summary>This study involve use drug call Thymoglobulin , approve US treat kidney transplant rejection Canada treat prevent kidney transplant rejection . This study evaluate effect Thymoglobulin induction therapy reduce dos calcineurin inhibitor incidence liver rejection provide basis future evaluation Thymoglobulin immunosuppressive agent help decrease incidence liver transplant rejection . Subjects meet inclusion exclusion criterion eligible participate study . Approximately 75 study subject 18 transplant center United States Canada enrol 12-month study .</brief_summary>
	<brief_title>Evaluation Thymoglobulin Induction Reduced Doses Calcineurin Inhibitors Liver Transplant Rejection</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Primary liver transplant recipient Model EndStage Liver Disease ( MELD ) criterion documentation Serum creatinine &gt; 1.5mg/dL time transplant , base value use calculate recent preoperative MELD Score liver allocation Ages great equal 18 year If female , must lactate ; must negative serum betahuman chorionic gonadotropin ( HCG ) test within 7 day prior Study Day 0 ( Day Transplant ) ; must agree practice acceptable reliable form contraception study Signed informed consent Living donor multiple organ transplant Prior solid organ bone marrow transplant recipient Fulminant hepatic failure Status 1 transplant ABO incompatible transplant Transplants utilize liver non heartbeating donor Liver transplant candidate &gt; 6 week analysis Donor positive serology hepatitis B surface antigen ( HBsAg ) Evidence human immunodeficiency virus ( HIV ) Autoimmune hepatitis History chronic steroid immunosuppressant use 90 day prior transplant , except inhaled corticosteroid treat asthma Recipient investigational therapy within 90 day prior transplant procedure Known contraindication administration rabbit antithymocyte globulin Acute viral illness History malignancy within 5 year , exception adequately treat localized squamous basal cell carcinoma skin without evidence recurrence , and/or hepatocellular carcinoma Illness primary liver disease ( e.g . severe ischemic heart disease , leave ventricular dysfunction , pulmonary disease ) , , opinion investigator , may significantly increase risk transplantation procedure Current drug alcohol abuse , opinion investigator , put subject risk poor compliance ( drug test require )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Anti-T cell antibody</keyword>
	<keyword>Primary Liver Transplantation Renal Dysfunction</keyword>
	<keyword>Liver Transplant Rejection</keyword>
	<keyword>Induction Therapy reduction Calcineurin inhibitor</keyword>
	<keyword>Primary Liver Transplantation</keyword>
	<keyword>Primary Transplant Rejection</keyword>
	<keyword>Transplantation , Liver</keyword>
	<keyword>Rejection , Transplant</keyword>
</DOC>